Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6445751 | 1.00 | CYP3A4 (0.38) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL6328 | 0.95 | CYP3A4 (0.38) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL19031749 | 0.93 | CYP3A4 (0.36) | CYP3A4TDP1 | |
| Hydrochloric Acid SCHEMBL8876479 | 0.93 | CYP3A4 (0.36) | CYP3A4TDP1 | |
| SCHEMBL6442588 | 0.90 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL197144 | 0.90 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL29179 | 0.90 | CYP3A4 (0.45) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL689027 | 0.87 | TDP1 (0.43) | CYP3A4TDP1ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL9322645 | 0.87 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL7164452 | 0.87 | TDP1 (0.43) | CYP3A4TDP1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158424-A1 | METHOD FOR PRODUCING DIPHOSPHINE MONOXIDE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2024-05-16 | — | — | US | disclosed |
| EP-4361162-A2 | METHOD FOR PRODUCING DIPHOSPHINE MONOXIDE | Takasago International Corporation (JP) | 2024-05-01 | — | — | EP | disclosed |
| CN-116135866-A | Bridged carboxylic acid-containing difunctional phosphine ligand, preparation method and application thereof | 中山大学 | 2023-05-19 | — | — | CN | disclosed |
| EP-2210876-B1 | HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST | TAKEDA PHARMACEUTICAL (JP) | 2015-05-20 | — | — | EP | disclosed |
| EP-2272851-B1 | FLUORINATED BORONIC ACID ESTER COMPOUND AND PROCESS FOR PRODUCTION THEREOF | UNIMATEC CO LTD (JP) | 2014-02-26 | — | — | EP | disclosed |
| EP-2325188-B1 | FLUORINE-CONTAINING BORONIC ACID ESTER COMPOUND AND METHOD FOR PRODUCING SAME | UNIMATEC CO LTD (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-8309580-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2210876-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
| EP-2192124-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND WITH THE TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
| US-20100072581-A1 | COMPOSITION FOR FILM FORMATION, INSULATING FILM, SEMICONDUCTOR DEVICE, AND PROCESS FOR PRODUCING THE SEMICONDUCTOR DEVICE | KABUSHIKI KAISHA TOSHIBA (JP) | 2010-03-25 | — | — | US | disclosed |
| US-5741438-A | Optically active biphenyl derivative, process for preparation thereof, liquid crystal composition containing the same as an effective component, and liquid crystal element using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-04-21 | — | — | US | disclosed |
| US-5422038-A | Ferroelectric liquid crystal material with sufficient spontaneous polarization, high speed response capability, wide temperature range | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-06-06 | — | — | US | disclosed |
| EP-0416946-B1 | Optically active naphthalene derivative, process for preparation thereof, liquid crystal composition containing the same as effective component, and liquid crystal element using the same | SUMITOMO CHEMICAL CO (JP) | 1994-11-09 | — | — | EP | disclosed |
| EP-0395390-B1 | Optically active biphenyl derivative, process for preparation thereof, liquid crystal composition containing the same as effective component, and liquid crystal element using the same | SUMITOMO CHEMICAL CO (JP) | 1994-09-28 | — | — | EP | disclosed |
| EP-0416946-A2 | Optically active naphthalene derivative, process for preparation thereof, liquid crystal composition containing the same as effective component, and liquid crystal element using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-03-13 | — | — | EP | disclosed |
| EP-0395390-A1 | Optically active biphenyl derivative, process for preparation thereof, liquid crystal composition containing the same as effective component, and liquid crystal element using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158424-A1 | METHOD FOR PRODUCING DIPHOSPHINE MONOXIDE | TDO2, SCO2, DUOX1 | CYP3A4 611/4885TDP1 1033/4885ESR1 4231/4885 |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | CYP3A4 834/4885TDP1 4750/4885ESR1 3264/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | CYP3A4 834/4885TDP1 4750/4885ESR1 3264/4885 |
| US-20100072581-A1 | COMPOSITION FOR FILM FORMATION, INSULATING FILM, SEMICONDUCTOR DEVICE, AND PROCESS FOR PRODUCING THE SEMICONDUCTOR DEVICE | C1S, MCM3, MRPS23 | CYP3A4 1415/4885TDP1 2327/4885ESR1 2184/4885 |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | GLP1R, GPR119, GCGR | CYP3A4 1502/4885TDP1 4801/4885ESR1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.